36th Annual San Antonio Breast Cancer Symposium: resumen de los conceptos clínicos más relevantes

Joaquin Gavilá; María Dolores Torregrosa; Angel Guerrero; Regina Gironés; Amparo Ruiz; Pedro López

doi:10.1016/j.senol.2013.04.001

36th Annual San Antonio Breast Cancer Symposium: resumen de los conceptos clínicos más relevantes

Translated title of the contribution: 36th Annual San Antonio Breast Cancer Symposium: Summary of the contributions with greatest clinical impact

Joaquin Gavilá, María Dolores Torregrosa, Angel Guerrero, Regina Gironés, Amparo Ruiz, Pedro López

Research output: Contribution to journal › Short survey › peer-review

Abstract

The San Antonio Breast Cancer Symposium, in which breast cancer management is updated from a multidisciplinary perspective, is considered the most important international meeting on breast cancer. Notable contributions this year included 10-year studies of adjuvant tamoxifen and a phase ii trial of letrozole with PD 0332991, a cyclin-dependent kinase 4/6 inhibitor. The present article summarizes, under distinct subheadings, the contributions with greatest clinical impact.

Translated title of the contribution	36th Annual San Antonio Breast Cancer Symposium: Summary of the contributions with greatest clinical impact
Original language	Spanish
Pages (from-to)	65-72
Number of pages	8
Journal	Revista de Senologia y Patologia Mamaria
Volume	26
Issue number	2
DOIs	https://doi.org/10.1016/j.senol.2013.04.001
State	Published - 2013
Externally published	Yes

Access to Document

10.1016/j.senol.2013.04.001

Cite this

@article{a9fcbf1138b54618af21da2de871b89f,

title = "36th Annual San Antonio Breast Cancer Symposium: resumen de los conceptos cl{\'i}nicos m{\'a}s relevantes",

abstract = "The San Antonio Breast Cancer Symposium, in which breast cancer management is updated from a multidisciplinary perspective, is considered the most important international meeting on breast cancer. Notable contributions this year included 10-year studies of adjuvant tamoxifen and a phase ii trial of letrozole with PD 0332991, a cyclin-dependent kinase 4/6 inhibitor. The present article summarizes, under distinct subheadings, the contributions with greatest clinical impact.",

keywords = "Annual San Antonio Breast Cancer Symposium meeting, Breast cancer, Chemotherapy, Radiotherapy",

author = "Joaquin Gavil{\'a} and Torregrosa, {Mar{\'i}a Dolores} and Angel Guerrero and Regina Giron{\'e}s and Amparo Ruiz and Pedro L{\'o}pez",

year = "2013",

doi = "10.1016/j.senol.2013.04.001",

language = "Espa{\~n}ol",

volume = "26",

pages = "65--72",

journal = "Revista de Senologia y Patologia Mamaria",

issn = "0214-1582",

number = "2",

}

TY - JOUR

T1 - 36th Annual San Antonio Breast Cancer Symposium

T2 - resumen de los conceptos clínicos más relevantes

AU - Gavilá, Joaquin

AU - Torregrosa, María Dolores

AU - Guerrero, Angel

AU - Gironés, Regina

AU - Ruiz, Amparo

AU - López, Pedro

PY - 2013

Y1 - 2013

N2 - The San Antonio Breast Cancer Symposium, in which breast cancer management is updated from a multidisciplinary perspective, is considered the most important international meeting on breast cancer. Notable contributions this year included 10-year studies of adjuvant tamoxifen and a phase ii trial of letrozole with PD 0332991, a cyclin-dependent kinase 4/6 inhibitor. The present article summarizes, under distinct subheadings, the contributions with greatest clinical impact.

AB - The San Antonio Breast Cancer Symposium, in which breast cancer management is updated from a multidisciplinary perspective, is considered the most important international meeting on breast cancer. Notable contributions this year included 10-year studies of adjuvant tamoxifen and a phase ii trial of letrozole with PD 0332991, a cyclin-dependent kinase 4/6 inhibitor. The present article summarizes, under distinct subheadings, the contributions with greatest clinical impact.

KW - Annual San Antonio Breast Cancer Symposium meeting

KW - Breast cancer

KW - Chemotherapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84924220088&partnerID=8YFLogxK

U2 - 10.1016/j.senol.2013.04.001

DO - 10.1016/j.senol.2013.04.001

M3 - Estudio breve

SN - 0214-1582

VL - 26

SP - 65

EP - 72

JO - Revista de Senologia y Patologia Mamaria

JF - Revista de Senologia y Patologia Mamaria

IS - 2

ER -

36th Annual San Antonio Breast Cancer Symposium: resumen de los conceptos clínicos más relevantes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this